FenFen Sun

FenFen Sun

Auto-generated profile, based on publicly available information

FenFen Sun

Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
HCHengyi Chen
Hengyi Chen
CLCaiyu Lin
Caiyu Lin
PTPeng Tao
Peng Tao
CHCheng Hu
Cheng Hu
CLConghua Lu
Conghua Lu
YHYong He
Yong He
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has sufficient clinical efficacy and satisfactory safety in ALK-positive non-small cell lung cancer (NSCLC) patients with or without brain metastasis. Alectinib has now become an important drug in the first-line treatment of advanced ALK-positive NSCLC; however, resistance is almost inevitable. The increased expression of hepatocyte growth factor (HGF) and its physiological receptor tyrosine kinase MET have been shown to be linked to acquired resistance to various tyrosine kinase inhibitors (TKIs), and this phenomenon has been observed in some ALK-positive NSCLC tumour tissues. In this study, we found that HGF levels in the culture supernatant of an ALK-positive cell line tended to increase with time and could be further increased by alectinib in a time-dependent manner. Exogenous or endogenous HGF did not cause resistance to the ALK/MET double-targeted small molecule inhibitor crizotinib, but it was an important cause of alectinib resistance. Furthermore, Gab1 was a key effector in the HGF/MET signal transduction pathway that mediated alectinib resistance. The antidiabetic drug metformin combined with alectinib overcame alectinib resistance triggered by HGF/MET through disrupting the complex between MET and Gab1, thereby inhibiting Gab1 phosphorylation and the activation of downstream signal transduction pathways. These results suggest that metformin combined with alectinib may be useful for overcoming alectinib resistance induced by the activation of the HGF/MET signalling pathway and improving the efficacy of alectinib.

3 November 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
LXLi-Xia Xie
Li-Xia Xie
FSFeng-Feng Sun
Feng-Feng Sun
BHBin-Feng He
Bin-Feng He
XZXiao-Feng Zhan
Xiao-Feng Zhan
JSJuan Song
Juan Song
XYXiao-Qun Ye
Xiao-Qun Ye

1 June 2018 in Respiratory Medicine
Verified
Journal Article
Closed access
FSFenfen Sun
Fenfen Sun
LLLi Li
Li Li
XLXiuqing Liao
Xiuqing Liao
XYXiaofeng Yan
Xiaofeng Yan
RHRui Han
Rui Han
GCGuoqiang Cao
Guoqiang Cao